Yazar "Saglam, Esra Kaytan" için listeleme
-
Chronomodulated Administration of Oxaliplatin plus Capecitabine (XELOX) as First Line Chemotherapy in Metastatic Colorectal Cancer Patients: Phase II Brunch Regimen Study.
Pilanci, Kezban Nur; Saglam, Sezer; Okyar, Alper; Yucel, Serap; Kara, Zeliha Pala; Ordu, Cetin; Saglam, Esra Kaytan (AMER SOC CLINICAL ONCOLOGY, 2015)… -
IS CHROMOSOMAL RADIOSENSITIVITY A PREDICTIVE TOOL FOR CANCER RISKS?
Ozar, Melek Ozlem Kolusayin; Orta, Tuncay; Dizdar, Yavuz; Saglam, Esra Kaytan; Saglam, Sezer; Turna, Akif; Okutan, Murat (Parlar Scientific Publications (P S P), 2021)There is an extensive landscape of genomic disruptions caused by environmental carcinogens. A major environmental mutagen that can trigger direct changes in the DNA is radiation. In certain places, ionizing radiation such ... -
Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+rectal cancer: Istanbul R-02 phase II randomized study
Senyurek, Sukran; Saglam, Sezer; Saglam, Esra Kaytan; Yanar, Hakan; Gok, Kaan; Tastekin, Didem; Akbas, Canan Koksal (Tech Science Press, 2023)Radiation therapy (RT) is typically applied using one of two standard approaches for preoperative treatment of resectable locally advanced rectal cancer (LARC): short-course RT (SC-RT) alone or long-course RT (LC-RT) with ... -
Prognostic significance of carbonic anhydrase IX overexpression in stage III non-small cell lung cancer patients after neoadjuvant treatment
Ibis, Kamuran; Saglam, Sezer; Saglam, Esra Kaytan; Firat, Pinar; Yilmazbayhan, Dilek; Toker, Alper; Pilanci, Kezban Nur (ELSEVIER GMBH, URBAN & FISCHER VERLAG, 2018)Background: To assess the prognostic importance of carbonic anhydrase IX (CA IX), a hypoxic biomarker, after neoadjuvant treatment in Stage III non-small cell lung cancer (NSCLC) patients. Methods: Tissue CA IX expression ...